Childhood Cancer Genomics (PDQ®)–Health Professional Version
SECTIONS
- General Information About Childhood Cancer Genomics
- Leukemias
- Non-Hodgkin Lymphoma
- Central Nervous System Tumors
- Hepatoblastoma and Hepatocellular Carcinoma
- Sarcomas
- Langerhans Cell Histiocytosis
- Neuroblastoma
- Retinoblastoma
- Kidney Tumors
- Melanoma
- Thyroid Cancer
- Multiple Endocrine Neoplasia Syndromes
- Changes to this Summary (12/20/2017)
- About This PDQ Summary
- View All Sections
Changes to this Summary (12/20/2017)
The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.
Added text to the Acute Lymphoblastic Leukemia (ALL) section about the characteristics of MEF2D-rearranged ALL (cited Gu et al., Liu et al., Suzuki et al., and Lilljebjörn et al. as references 74, 75, 76, and 77, respectively).
Added text to the Acute Lymphoblastic Leukemia (ALL) section about the characteristics of ZNF384-rearranged ALL (cited Hirabayashi et al., Qian et al., Shago et al., and Yao et al. as references 78, 79, 80, and 81, respectively).
Added text to the Acute Lymphoblastic Leukemia (ALL) section about the PAX5 amplification in B-cell ALL cases (cited Schwab et al. as reference 89).
Revised text in the Acute Myeloid Leukemia (AML) section to state that although both RUNX1-RUNX1T1 and CBFB-MYH11 fusion genes disrupt the activity of core-binding factor, cases with these genomic alterations have distinctive secondary mutations.
This section was comprehensively reviewed, extensively revised, and reformatted.
Added text to the Langerhans Cell Histiocytosis (LCH) section to state that in a study that included 48 patients with BRAF V600E–mutated LCH, the BRAF V600E allele was detected in circulating cell-free DNA in 100% of patients with risk-organ–positive multisystem LCH, 42% of patients with risk-organ–negative LCH, and 14% of patients with single-system LCH (cited Héritier et al. as reference 14).
This summary is written and maintained by the PDQ Pediatric Treatment Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ® - NCI's Comprehensive Cancer Database pages.
No hay comentarios:
Publicar un comentario